TargetRx Completes $9.6M Financing Round

Funding Provides Investment Capital to Support New Growth Initiatives

Horsham, PA - April 7, 2008 - TargetRx Inc. today announced that the company has received $9.6M of venture funding led by existing investors Quaker BioVentures, New Enterprise Associates (NEA) and Domain Associates. This infusion of capital will further support the company's plans for growth and the development of innovative new products designed to help the pharmaceutical industry improve sales and marketing effectiveness as well as drive overall business performance.

"Over the past several years, TargetRx has established itself as the only company that can offer pharmaceutical companies the information and insight that will enable them to redefine their sales and marketing strategies and remain competitive in today's marketplace," said Richard Kollender, chairman of the TargetRx board of directors and a partner at Quaker BioVentures. "With an expanding customer base, seasoned senior management team and aggressive product development plans, the company is well-positioned for future success."

"The support of our investors is a great endorsement of our business model and our mission to optimize pharmaceutical sales and marketing effectiveness," said Craig Scott, CEO and president of TargetRx. "This funding will be used to further strengthen our management team, scale our current capabilities and increase the pace of our new product development."

Since 1999, TargetRx has worked with the majority of the top 30 pharmaceutical companies in the U.S. to increase market share for some of the industry's leading brands. Through the company's unique database of physician insights, TargetRx enables pharmaceutical companies to measure, manage and improve performance against the key drivers of physician prescribing behavior.

About TargetRx

TargetRx provides pharmaceutical and biotech companies with unique insight into the true drivers of product choice and adoption for their brands, helping clients to confidently take the actions that will grow their businesses and help patients. Serving the majority of the top 30 pharmaceutical and biotech companies, TargetRx enables clients to significantly improve the launch of new products and indications, physician segmentation and targeting, creation of professional messaging and materials, and sales and marketing execution and effectiveness. All TargetRx solutions are powered by our AdvantageBuilderSM normative database and validated predictive models, created from capturing in-depth physician attitudes on the "four forces" of prescribing - product, payor, promotion and patient - on new launches, marketing campaigns and physician-rep interactions on over 500 pipeline and inline brands and modeling these attitudes against actual prescribing behavior. For more information, visit www.targetrx.com.

Media Contact:

Joe Ford
Phone: 215-444-8722
jford@targetrx.com